Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene therapy Elevidys in the wake of the death of a patient who received the ...

Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of ...

Learn more about whether Alvotech or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Sarepta already markets three drugs for DMD that have to be taken chronically, but SRP-9001 offers the possibility of a one-shot therapy for the disease. Roche has exclusive rights to the therapy ...

J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $182.00. The company’s shares closed yesterday at ...

The global gene therapy market is projected to grow at a significant CAGR of 20% from 2024 to 2029. This growth is driven by ...

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sandoz is alleging Amgen's patent actions were anticompetitive.

Roche subsidiary Genentech received FDA approval for tenecteplase, brand name TNKase, as a treatment for acute ischemic stroke in adults. Genentech said TNKase is the first stroke medicine ...